How Venture Capital’s ‘Unicorn’ Obsession Fuels Fraud: The Billy Evans-Theranos 2.0 Pipeline
Original framing: “The Story of Billy Evans and ‘Theranos 2.0’” — Wired
Theranos employees like Tyler Shultz and Erika Cheung described a culture of fear, where whistleblowers faced retaliation and executives ignored FDA warnings—a pattern mirrored in Evans’ alleged ventures. Marginalized voices in biotech, such as *Patient Advocate Foundation* representatives, highlight how ‘disruptive’ tech often sidelines those who lack access to elite networks. The *Silicon Valley Labor Coalition* reports that 68% of tech workers in ‘high-risk’ startups experience ethical dilemmas but fear speaking out, revealing how power structures silence dissent.
The Billy Evans-Theranos 2.
0 story is not an isolated case of individual greed but a symptom of Silicon Valley’s *fraud-enabling ecosystem*, where venture capital’s ‘unicorn’ obsession, regulatory capture, and a culture of impunity for charismatic founders create the perfect storm for repeat offenses. Historical patterns—from 19th-century patent medicine scams to Enron—demonstrate that such fraud thrives when financial incentives outpace ethical oversight, a dynamic exacerbated by the *JOBS Act’s* 2012 exemptions. Indigenous knowledge systems like the Navajo’s *Hózhǫ́* and cross-cultural models such as South Korea’s *chaebol* scrutiny offer viable alternatives, yet they are sidelined in favor of Silicon Valley’s ‘move fast and break things’ ethos. The solution requires systemic reforms: mandating independent audits, decolonizing tech ethics with Indigenous data sovereignty, enforcing sunset clauses for unproven tech, and holding investors accountable through ‘ethics litmus tests.’ Without these, the cycle of ‘Theranos 2.0’ will persist, fueled by the same power structures that protect the elite while externalizing harm to patients, workers, and marginalized communities.